Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Theratechnologies Inc T.TH

Alternate Symbol(s):  THTX

Theratechnologies Inc. is a Canada-based clinical-stage biopharmaceutical company. The Company is focused on the development and commercialization of therapies addressing unmet medical needs. It markets prescription products for people with human immunodeficiency viruses (HIV) in the United States. The Company's research pipeline focuses on specialized therapies addressing unmet medical needs in HIV, nonalcoholic steatohepatitis (NASH) and oncology. Its medicines include Trogarzo and EGRIFTA SV (tesamorelin for injection). Trogarzo (ibalizumab-uiyk) injection is a long-acting monoclonal antibody which binds to domain 2 of the CD4 T cell receptors. EGRIFTA SV (tesamorelin for injection) is approved in the United States for the reduction of excess abdominal fat in people with HIV who have lipodystrophy. Its portfolio includes Phase I clinical trial of sudocetaxel zendusortide (TH1902), a novel peptide-drug conjugate (PDC), in patients with advanced ovarian cancer.


TSX:TH - Post by User

Comment by qwerty22on Jul 25, 2021 11:56pm
88 Views
Post# 33602842

RE:RE:RE:A lot of divirsity of opinions here

RE:RE:RE:A lot of divirsity of opinions here

Walk me thru an ATM if you can. They usually sell over the course of a few weeks/months? Or it can vary a lot?  Can it exist and never reach it's total shares sold or do they always end up selling all? It says the company has complete control of the flow of shares, is that the usual wording? Is that how it plays out in practice or will Cantor dictate the pace of share sales?


Wino115 wrote:

That's the right question we need to answer for ourselves.  It's definitely positive for Cantor (at some point).  Positive for management because they own very little and now can raise money easily if they want, when they want and at any price they choose.  


A positive to me would be if Cantor does a very in-depth, solid, convincing research report valuing the full company and looking at future scenarios in that valuation.  You could say it's a positive if any price they ultimately sell at is higher than where it will be in a year.  But of course that means the news flow would be negative.  I guess you could say it's a positive if the share spikes to a ridiculous level and they sell it out with minimal dilution and the share comes back to reality.  But this assumes they are great market timers and the new investors are not.  


I suppose it would be a positive if a good NASH deal requires them to fund more of the trial in order to attract a quality partner. Another sce ariowpuld be they get accelerated approval and break through therapy and FDA tells them to do a quick confirmatory P3 and allows them to start selling it on a experimental basis post a P2 with good news.  In that case they need to ramp sales in US quickly.  Having an ATM shows the FDA you can move ahead just as rapidly as them. 

 

qwerty22 wrote:

 

What if we assumed a very positive outcome in cancer. What if people came knocking looking to invest in the SORT1 technology. Would the ATM be a strong tool in managements armoury to take advantage of that? 

We are all naturally suspicious. Are there any circumstances where the ATM is a positive to us?


 

SPCEO1 wrote:
Reading through the posts reveals a very wide range of opinions. TH should be quick to clear things up - clear shareholder communications are key to success in such situations. Hopefully, we will get that soon. There may be a reason why Leah Gibson has not tried to answer my questions yet - she can't until another shoe falls. But as soon as then can get all of us singing from the same song sheet, the better.

 

 





<< Previous
Bullboard Posts
Next >>